Ebola Vaccine Trial in DR Congo: Bundibugyo Virus, TUMAINI Clinical Trial, Working and Significance of Trial

Why in news?

On 23 October 2026, the first participant was vaccinated in the TUMAINI Phase 2/3 clinical trial in Bunia, in the Democratic Republic of the Congo.

Key Facts 

What is Ebola Disease?

• A serious infectious disease caused by viruses belonging to the Orthoebolavirus genus. 
• It can cause severe illness, including fever, weakness, vomiting, diarrhoea and, in some cases, internal or external bleeding. 
• Transmission generally occurs through direct contact with the blood or other body fluids of an infected person who is symptomatic, or through contaminated materials. 
• Early diagnosis, isolation, appropriate medical care, infection prevention and community cooperation are essential to controlling outbreaks.
• The WHO identifies four Ebola virus species known to cause disease in humans:

What is the Bundibugyo Virus outbreak?

• The current outbreak was declared in the Democratic Republic of the Congo on 15 May 2026. 
• According to the WHO's update published on 23 October 2026, the outbreak had resulted in 9,704 confirmed cases and 4,687 deaths in DR Congo as of 20 October 2026. 
• By 20 October, Kenya had reported imported cases, and Nigeria had confirmed an imported case. 
• The WHO has emphasised surveillance, contact tracing, preparedness and coordination between neighbouring countries. 
• Several factors complicate the response:
  • Delayed identification of infections and access to treatment.
  • Difficulties in tracking contacts across large or remote areas.
  • Insecurity and humanitarian challenges.
  • Movement of people across national borders.
• The absence of an approved vaccine specifically for Bundibugyo virus disease.

What is the TUMAINI Clinical Trial?

• Ervebo-the first candidate: A licensed vaccine against Ebola virus disease caused by the Ebola virus species. Its effectiveness against Bundibugyo virus in humans remains unproven. 
• Oxford-Serum Institute candidate: A Bundibugyo-specific vaccine candidate using the ChAdOx1 adenoviral-vector platform is being developed by the University of Oxford in collaboration with the Serum Institute of India. Preparations are underway for its inclusion in the trial.
• Moderna candidate: A second Bundibugyo-specific candidate, developed by Moderna using mRNA technology, is also being prepared for evaluation. Its inclusion will depend on the research and regulatory process. 

How does the trial work?

Step 1: Identify cases and contacts

Health teams identify confirmed cases and trace people who may have been exposed to the virus.

Step 2: Focus on high-risk contacts

Ring vaccination targets contacts of confirmed cases and other eligible high-risk contacts, according to the approved trial protocol.

Step 3: Evaluate vaccine candidates

Researchers assess safety, immune responses and the ability of vaccines to prevent disease.

Step 4: Use the evidence

Findings can guide future decisions on vaccine effectiveness, safety and public-health policy.

Why is the trial significant?

• Potential to save lives: If an effective vaccine is identified, it could help protect people at risk and strengthen the response to current and future Bundibugyo virus outbreaks.
• Evidence-based vaccine policy: A vaccine's effectiveness against one virus does not establish its effectiveness against another. The trial can help replace uncertainty with clinical evidence, supporting better-informed vaccination decisions. 
• Faster vaccine development: The adaptive platform approach can help evaluate multiple candidates through a shared framework. It may also support the development of vaccines specifically designed for Bundibugyo virus.
• Stronger African research capacity: The trial is led by DR Congo's national health authorities and involves Congolese research institutions alongside international partners. It illustrates the importance of locally led scientific research during public-health emergencies. 

Government Initiatives and International Cooperation

• DR Congo Ministry of Health: Provides national leadership and oversight.
• World Health Organization (WHO): Provides technical guidance, scientific support and assistance with outbreak response.
• Africa CDC: Supports regional coordination and African-led research.
• Coalition for Epidemic Preparedness Innovations (CEPI): Supports the development and evaluation of vaccine candidates.
• Institut National de Recherche Biomédicale (INRB) and University of Antwerp: Co-lead and co-sponsor the trial.
• Serum Institute of India and University of Oxford: Collaborate on a Bundibugyo-specific vaccine candidate.

Major Challenges

• Scientific uncertainty: Ervebo's protection against Bundibugyo virus in humans is not yet established.
• Speed versus safety: Rapid research must retain rigorous testing and ethical oversight
• Contact tracing: Missed contacts can undermine ring vaccination and outbreak surveillance.
• Public trust: Misinformation and distrust can reduce participation in vaccination and research.
• Healthcare access: Remote areas and insecurity can make treatment and follow-up difficult.

FAQs